Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term safety and efficacy of TAK-536 + amlodipine + hydrochlorothiazide in essential hypertension
jRCT2080222638Phase 3
- Sponsor
- Takeda
- Start
- Oct 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of azilsartan + amlodipine + hydrochlorothiazide in essential hypertension, sponsored by Takeda.
02
Drugs
azilsartan + amlodipine + hydrochlorothiazide
03
Conditions
essential hypertension
Beyond the preview
Go deeper on jRCT2080222638.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080222638.